Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalin

Código QR

Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalin

Raymond R Tjandrawinata,1 Effi Setiawati,2 Ratih Sofia Ika Putri,2 Vincent Angga Gunawan,2 Fenny Ong,1 Liana W Susanto,1 Dwi Nofiarny11Dexa Laboratories of Biomolecular Sciences, Cikarang, West Java, Indonesia; 2PT Equilab International Bioavailability and Bioequivalence Laboratory, Jakarta, Indones...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tjandrawinata RR, Setiawati E, Putri RSI, Gunawan VA, Ong F, Susanto LW, Nofiarny D
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/0177166afbd64b0ebda8d85e6ab4ab99
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Pharmacokinetic equivalence study of nonsteroidal anti-inflammatory drug etoricoxib
por: Tjandrawinata RR, et al.
Publicado: (2018)

Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers
por: Farr SJ, et al.
Publicado: (2015)

A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation
por: van Rossem K, et al.
Publicado: (2013)

An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614)
por: Wollenberg LA, et al.
Publicado: (2015)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
por: Persson PB
Publicado: (2015)

Population pharmacokinetics of olprinone in healthy male volunteers
por: Kunisawa T, et al.
Publicado: (2014)

Pharmacokinetics and skin-tissue penetration of daptomycin in rats
por: Matsumoto K, et al.
Publicado: (2015)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
por: Frost C, et al.
Publicado: (2014)

Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma
por: Li Zhang, et al.
Publicado: (2021)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum]
por: Frost C, et al.
Publicado: (2018)

Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia
por: Xia Pu, et al.
Publicado: (2021)

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model
por: Lozano R, et al.
Publicado: (2013)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
por: Upreti VV, et al.
Publicado: (2013)

Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials
por: Vermunt M, et al.
Publicado: (2021)

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model [Corrigendum]
por: Lozano R, et al.
Publicado: (2013)

Development of physiologically‐based pharmacokinetic models for standard of care and newer tuberculosis drugs
por: Helen Humphries, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers
por: Nagelschmitz J, et al.
Publicado: (2014)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
por: Cui Y, et al.
Publicado: (2013)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
por: Cui Y, et al.
Publicado: (2014)

Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia
por: Ekaterina Gibiansky, et al.
Publicado: (2021)

Population Pharmacokinetic Model of Plasma and Cellular Mycophenolic Acid in Kidney Transplant Patients from the CIMTRE Study
por: François Riglet, et al.
Publicado: (2020)

ModVizPop: A shiny interface for empowering teams to perform interactive pharmacokinetic/pharmacodynamic simulations
por: Pavan Vaddady, et al.
Publicado: (2021)

Enantiomer-selective pharmacokinetics, oral bioavailability, and sex effects of various alpha-lipoic acid dosage forms
por: Hermann R, et al.
Publicado: (2014)

Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
por: Chetan Rathi, et al.
Publicado: (2021)

The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein&ndash;Barr virus disease
por: Heather&nbsp;E Vezina, et al.
Publicado: (2009)

Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically‐based pharmacokinetic model
por: Khaled Abduljalil, et al.
Publicado: (2021)

Development of best practices in physiologically based pharmacokinetic modeling to support clinical pharmacology regulatory decision‐making—A workshop summary
por: Daphney Jean, et al.
Publicado: (2021)

A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males
por: Kalman DS, et al.
Publicado: (2015)

Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug–drug interaction study
por: Tompson DJ, et al.
Publicado: (2014)

Comparisons of Four Protein-Binding Models Characterizing the Pharmacokinetics of Unbound Phenytoin in Adult Patients Using Non-Linear Mixed-Effects Modeling
por: Heajin Jun, et al.
Publicado: (2020)

Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole
por: Patel C, et al.
Publicado: (2011)

A population pharmacokinetic‐pharmacodynamic model of YH12852, a highly selective 5‐hydroxytryptamine 4 receptor agonist, in healthy subjects and patients with functional constipation
por: Siun Kim, et al.
Publicado: (2021)

Tizanidine-induced acute severe cystitis in a female taking famotidine
por: Poudel RR, et al.
Publicado: (2015)

Transdermal Delivery of Telmisartan: Formulation, in vitro, ex vivo, Iontophoretic Permeation Enhancement and Comparative Pharmacokinetic Study in Rats
por: Teaima M, et al.
Publicado: (2021)

A Phase I study evaluating the effect of age and weight on the pharmacokinetics of an injectable formulation of diclofenac solubilized with hydroxypropyl-β-cyclodextrin
por: Goldwater R, et al.
Publicado: (2016)

Population Pharmacokinetics of CC-122
por: Cheng Y, et al.
Publicado: (2021)

Effects of puerarin on the pharmacokinetics of triptolide in rats
por: Qingfa Wang, et al.
Publicado: (2019)

Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections
por: Wiederhold NP
Publicado: (2015)

Pharmacokinetic Disposition Difference Between Cyclosporine and Voclosporin Drives Their Distinct Efficacy and Safety Profiles in Clinical Studies
por: Li Y, et al.
Publicado: (2020)

Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections
por: Matsumoto K, et al.
Publicado: (2016)